血必净注射液治疗慢性阻塞性肺疾病合并社区获得性肺炎的临床观察

发布时间：2018-04-18 11:10

本文选题：血必净 + 慢性阻塞性肺疾病　；参考：《中国药房》2017年14期

【摘要】：目的:探讨血必净注射液治疗慢性阻塞性肺疾病合并社区获得性肺炎的临床疗效及安全性。方法:选取我院2013年2月-2015年1月收治的慢性阻塞性肺疾病合并社区获得性肺炎患者88例,按随机数字表法分为对照组和观察组,各44例。对照组患者给予抗感染、化痰、补液、营养支持等常规治疗,观察组患者在对照组基础上加用血必净注射液50 m L加入0.9%氯化钠注射液100 m L中,ivgtt,滴注时间30~40 min,bid,连续治疗10 d。观察两组患者临床疗效、抗菌药物使用时间及治疗前后肺功能指标[第1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC及肺活量(VC)],并记录不良反应发生情况。结果:观察组患者总有效率为88.64%,显著高于对照组的70.45%,差异有统计学意义(P0.05)。观察组患者抗菌药物使用时间明显短于对照组,差异有统计学意义(P0.05)。两组患者治疗前FEV1、FVC、FEV1/FVC、VC水平比较,差异均无统计学意义(P0.05);治疗后,两组患者FEV1、VC显著改善,且观察组显著优于对照组,差异均有统计学意义(P0.05),而FVC、FEV1/FVC治疗前后及组间比较,差异均无统计学意义(P0.05)。两组患者均未见明显不良反应发生。结论:血必净注射液治疗慢性阻塞性肺疾病合并社区获得性肺炎疗效显著,能明显缩短抗菌药物使用时间,改善患者肺功能,且安全性较好。
[Abstract]:Objective: to investigate the clinical efficacy and safety of Xuebijing injection in the treatment of chronic obstructive pulmonary disease with community acquired pneumonia.Methods: 88 patients with chronic obstructive pulmonary disease complicated with community-acquired pneumonia from February 2013 to January 2015 were divided into control group (n = 44) and observation group (n = 44).The patients in the control group were treated with routine therapy, such as anti-infection, phlegm reduction, fluid replacement and nutritional support. The patients in the observation group were treated with Xuebijing injection 50 mL plus 0.9% sodium chloride injection 100 mL iv gttt for 3040 min bid for 10 days.The clinical efficacy, time of use of antimicrobial agents and pulmonary function indexes before and after treatment were observed in the two groups [forced expiratory volume (FEV1), forced vital capacity (FVC), FEV 1 / FVC and vital capacity (VC)] before and after treatment, and adverse reactions were recorded.Results: the total effective rate of the observation group was 88.64, which was significantly higher than that of the control group (70.45%). The difference was statistically significant (P 0.05).The time of antimicrobial use in the observation group was significantly shorter than that in the control group, and the difference was statistically significant (P 0.05).Before treatment, there was no significant difference in FEV1 / FVC+ VC levels between the two groups. After treatment, FEV1 + VC in the two groups was significantly improved, and the observation group was significantly better than the control group (P 0.05), and the FVCFEV1 / FVC was significantly higher than that in the control group (P 0.05), while FVCFEV1 / FVC was compared between the two groups before and after FVCFEV1 / FVC treatment.The difference was not statistically significant (P 0.05).No significant adverse reactions occurred in both groups.Conclusion: Xuebijing injection is effective in the treatment of chronic obstructive pulmonary disease with community-acquired pneumonia. It can shorten the time of use of antimicrobial agents and improve the pulmonary function of the patients.
【作者单位】：重庆市第七人民医院呼吸科;
【分类号】：R563

【相似文献】